23andMe collapse shakes India genetic testing market and could reshape how DNA services scale

A pioneer’s value crash raises the real question

23andMe, once a standout in direct-to-consumer genetic testing, has seen its momentum fade and market value fall sharply. Its setback highlights tough commercialization hurdles—costs, competition, and sustained demand—that could influence how India’s genetic-testing market grows. Yet the disruption may also open room for smarter, locally aligned offerings and stronger partnerships across healthcare.